Loading
companiesCompany
Medigene
Medigene is a Munich-area biotech that develops T-cell receptor therapies and once sold a dendritic-cell vaccine programme; its earlier oncology products included the drug Veregen and phase 3 trials that carry its name.
Also called: MediGene AGMedigene AG
Overview
Medigene AG, founded in 1994 and based in Planegg near Munich, discovers T-cell receptors for engineered T-cell therapies against solid tumours and licenses them to partners. Earlier it developed and sold Veregen (sinecatechins) and EndoTAG-1, a cationic liposomal paclitaxel taken to phase 3 in pancreatic cancer by its licensee, and ran a dendritic-cell vaccine programme in acute myeloid leukaemia. Its trials are registered on ClinicalTrials.gov under Medigene as lead sponsor.
Similar pages
- CompanyArgos Therapeutics
Shares Dendritic cell vaccines, Pivotal (registrational) trial, Clinical trial.
- CompanyLisata Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyVion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanySunesis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyPregLem
- CompanyDelta-Fly Pharma
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.